Objective: To identify factors predicting for recurrence in vulvar cancer patients undergoing surgical treatment.
V ulvar cancer (VC) represents an infrequent gynecological malignancy, accounting for <5% of all gynecological cancers. 1 Squamous cell carcinoma is the most prevalent subtype. 1, 2 Traditionally, curative treatment of squamous cell VC includes radical vulvectomy plus (superficial and deep) inguinal-femoral lymphadenectomy. 3 However, growing evidence suggested that less invasive procedures (ie, simple vulvectomy, wide local excision, sentinel node biopsy) provide similar long-term results, minimizing morbidity. [3] [4] [5] Although several studies aimed to report the safety and long-term oncologic effectiveness or even less demolitive procedures existed, [3] [4] [5] [6] only few investigations investigated possible risk factors for developing failure and often did not subdivide for the occurrence of different patterns of failure (ie, local, regional, and distant). [6] [7] [8] Hence, in the present study we aimed to report predictors of failure in squamous cell VC. In addition, we sought to describe outcomes of a consecutive series of squamous cell VC, and how the introduction of sentinel node biopsy and less radical vulvar surgery influenced long-term survival outcomes.
METHODS
We searched for the data of women who underwent primary surgical treatment of vulvar cancer at the Gynecologic Oncology Unit of University of Insubria, Ospedale di Circolo, Fondazione Macchi (Varese, Italy), between January 1, 1990 and December 31, 2013. In our institution, research activities involving the study of existing data are exempt from the requirement for institutional review board (IRB) approval. Patients gave written consent for the use of personal information for health research.
Inclusion criteria included: (1) age 18 years or above; (2) squamous cell VC; and (3) follow-up longer than 6 months. Patients with nonsquamous cell VC (eg, mammary-like, sarcoma, Paget disease) were excluded as the surgical aim for staging differed from that with squamous-cell and follow updata would be skewed. 9 Age, body mass index, American Society of Anaesthesiologists (ASA) score, comorbidity, details of surgical procedure, presence of premalignant lesions, histologic findings, and follow-up evaluations for each patient were recorded. Comorbidities level was assessed by Charlson comorbidity index; Charlson comorbidity index predicts the 10-year mortality for a patient who may have a range of comorbidity conditions. 10 The taxonomy proposed by the World Health Organization (WHO) was used to designate histologic subtypes. 11 The degree of glandular differentiation and cytologic atypia to determine architectural grade and stage were in accord with the new International Federation of Obstetrics and Gynecologists (FIGO) criteria. 1 Preoperative workup included gynaecological inspection (including vulvoscopy) cervical smear, inguinal ultrasound, 12 chest x-ray, and abdominal computed tomography (if distant lesions were suspected). Surgical technique for VC treatment included wide local excision, emi-vulvectomy, simple vulvectomy, and radical vulvectomy. Detailed surgical techniques for the management of VC are reported elsewhere. 3 In addition to local treatment inguinal lymph node dissection was performed. Superficial and deep inguinal lymphadenectomy was represented the standard of care. However, in 2000, we started to perform sentinel node biopsy. Lymphatic mapping and sentinel node biopsy was performed using a radiocolloid and a handheld gamma counter (that was passed over the groin area to identify lymph nodes emitting the tracer). 5, 13 In our department, indication for the execution of sentinel node biopsy included the presence of squamous cell tumour <4 cm and a clinical stage T1 or T2.
Follow-up was planned every 3 months in the first 2 years, then every 6 months for the first 5 years, and annually thereafter according to institutional recommendations. Survival data were abstracted from a dedicated database maintained by trained residents and prospectively updated on a regular basis. Rigorous efforts, including telephonic interviews, were done to improve quality of data reporting. Dates and sites of recurrence were recorded. Recurrences were classified in local (ie, vaginal), regional (ie, lymphatic pelvic and para-aortic), and distant (ie, hematogenous, peritoneal, and other lymphatic).
Statistical Analysis
Data were summarized using standard descriptive statistics. Duration of follow-up was calculated from the date of surgical treatment to the date of death or last follow-up. Disease-free survival (DFS) and overall (OS) survivals within the first 5 years were estimated using the Kaplan-Meier method. Risk factors were evaluated for an association with DFS and OS respectively, based on fitting univariable Cox proportional hazards models. Multivariable models were fit using stepwise variable selection methods considering all variables with a P-value <0.20 based on univariable analysis. Associations were summarized by calculating odds ratios (ORs) or hazard ratios (HRs) and corresponding 95% confidence intervals (CIs). All calculated P-values were 2-sided and P-values <0.05 were considered statistically significant. Analyses were performed using the GraphPad Prism version 6.0 for Mac (GraphPad Software, San Diego, CA) and IBM-Microsoft SPSS version 20.0 for Mac.
RESULTS
The study population included 101 patients affected by squamous-cell VC: 64 (63%) FIGO stage I, 12 (12%) stage II, 20 (20%) stage III, and 5 (5%) stage IV. Table 1 reports patientspecific, disease-specific, and treatment-specific characteristics for these patients. Median age of patients was 75 (range, 33 to 99) years old. Wide local excision, emi-vulvectomy, simple vulvectomy, and radical vulvectomy were performed in 14 (14%), 21 (21%), 13 (13%), and 53 (52%) cases, respectively. Twenty-seven (27%) and 54 (53%) patients had sentinel node biopsy and inguinal lymphadenectomy, respectively, whereas lymph node dissection was omitted in 20 (20%) patients. Considering 81 (80%) patients undergoing lymphadenectomy, we observed that, independently, FIGO grade 3 increased the risk to detect positive inguinal nodes (odds ratio [OR]: 1.4; 95% confidence interval [CI], 1.06-1.84; P = 0.01), whereas the presence of concomitant Lichen reduced the risk to have positive nodes (OR: 0.79; 95% CI, 0.65-0.97; P = 0.03). Univariate and multivariate analyses reporting associations between patients' characteristics and the presence of positive nodes are reported in Table 2 .
After a mean (SD) follow-up of 37.6 (22.1) months, 21 (21%) recurrences occurred. Five-years DFS and OS were 77% and 82%, respectively (Fig. 1 ). Looking at factors influencing survival outcomes, we observed that, at univariate analysis, tumor diameter >4 cm, stromal invasion >2 mm, positive node, lymph node extracapsular involvement, advanced stage of disease, and FIGO grade influenced DFS (P < 0.05), whereas radical vulvectomy, positive node, lymph node extracapsular involvement, and advanced stage of disease influenced OS (P < 0.05). However, at multivariate analysis only stromal invasion >2 mm (hazard ratio [HR]: 4.9 [95% CI, 1.17-21.1]; P = 0.04) and extracapsular lymph node involvement (HR: 9.0 [95% CI, 1.17-69.5]; P = 0.03) correlated with worse DFS, whereas no factor independently correlated with OS (Table 3) .
Local, regional, and distant failures were recorded in 14 (14%), 6 (6%), and 3 (3%) patients, respectively. As the low rate of distant recurrence, we evaluated only predictors of local and distant failure. Table 4 reports factors influencing the occurrence of recurrence rate by site. At multivariate analysis stromal invasion >2 mm and lymph node extracapsular involvement predicted for local (HR: 18.6; 95% CI, 2.18-159.2) and regional recurrence (HR: 1.6; 95% CI, 1.14-1.76), respectively, whereas margin status and surgical radicality did not influence local and regional failure rates.
DISCUSSION
The present study evaluated patterns of recurrence of VC and investigated the importance of difference prognostic factors to predict the occurrence of local and regional failure, thus demonstrating a number of noteworthy findings. First, we reported that overall 1 out of 5 patients experience recurrence of disease, with local, regional, and distant recurrence rate of about 14%, 6%, and 3%, respectively. Second, we observed that the presence of concomitant preneoplastic lesions (ie, Lichen) and FIGO grade 3 squamous cell tumor are associated with a reduced and increased risk of lymphatic spread, respectively. Third, our findings suggested that stromal infiltration >2 mm and lymph node extracapsular involvement are the main factors predicting for worse DFS. In particular, we observed that stromal invasion >2 mm and lymph node extracapsular involvement predict for the occurrence of local and regional failure, respectively, whereas no factors, independently, influence OS. VC is one of the less common gynaecological cancers and the role of its prognostic factor is far from clear. Although several studies suggested that nodal status, tumor diameter, and stroma invasion are the main prognostic factors, 1, 14 to date no data correlate predictors with the occurrence of different patterns of recurrence (ie, local, regional, and distant).
In 2009, the new FIGO 2009 staging system modified stage assignment of VC patients, down-staging patients with large tumor diameter (lesion >2 cm) and loco-regional disease (ie, tumor of any size with adjacent spread (1/3 lower urethra, 1/3 lower vagina and anus) and underlining the importance of nodal status, including the occurrence of lymph node extracapsular spread. 1 The present study corroborates these findings. In fact, we observed that tumor diameter was not independently associated with worse prognosis, whereas lymph node extracapsular spread represented one of the main important prognostic factors.
Notwithstanding, in contrast to our results, a recent, large (including 486 patients), multicenter study, focusing on the impact of this new staging system on prognosis of surgically treated VC, suggested that tumor diameter is an important predictors for recurrence. However, this study, in agreement with our results, underlined the importance of lymph node extracapsular tumor spread as an important prognostic factor for VC. 1 Interestingly, albeit, our study is not developed and powered to compare the procedure-related outcomes, we observed that less radical procedures (ie, wide excision, emivulvectomy, and simple vulvectomy) do not influence the occurrence of local failure, thus corroborating the growing evidence that questioned the routinely embrace of radical approach. [3] [4] [5] Therefore, although our results have to be considered preliminary, owing the limited sample size of the study, we have to consider that less radical procedures seems uphold the oncologic results of aggressive treatments, potentially minimizing morbidity. In addition, the role of adjuvant therapy in VC deserves to be addressed. We observed that adjuvant vaginal and inguinal radiotherapy had not influenced the risk of developing local and regional failure. We can speculate that the relative low sample size of patients undergoing adjuvant therapy influenced these results. Moreover, as the older age of patients included adjuvant therapy is generally delivered only in patients at highest risk of failure. However, in this high-risk group local/ regional factors are more important to influence the occurrence of failure than radiotherapy. Of note, this latter point is corroborated by other studies on this issue. [15] [16] [17] In particular, Woelber et al, 16 suggested that the potential beneficial effects of radiotherapy are reduced by the presence of multiple nodal metastases. Similarly, Fons et al, 17 reported that radiotherapy is ineffective in case of nodal spread.
The main weaknesses of the present study include the inherent biases of a retrospective, single centre study design. In addition, the relative small sample size may impair the interpretation of our results. In fact, a larger sample size would be strengthening our findings, thus allowing a more accurate comparison on the effects of surgical (plus or minus adjuvant) treatments. The main strength of the present study includes the innovative study design. In fact, to the best of our knowledge, this is the first study evaluating site-specific DFS in squamouscell VC.
In conclusion, the present study investigated prognostic factors for VC patients. We observed that stromal invasion >2 mm and lymph node extracapsular spread correlate with local and regional failure. Although our findings have to be considered preliminary and need to be confirmed by larger prospective investigations, the present results allow to identify patients at high risk of recurrence, for whom more aggressive treatment or surveillance are necessary. Studies evaluating the efficacy and effectiveness of different adjuvant treatments are warranted. Further attempts and constant attention are needed to improve outcomes of VC patients.
